Overview
Commercial Development Co. provides property management, premises rental, facilities maintenance, outsourced staffing, fleet hiring and technical services, primarily for its sole client, Commercial Bank of Ceylon. Its revenue model is therefore service-led and closely tied to the operating requirements of that banking group.
The key change is a widening gap between top-line activity and profitability: the latest quarter delivered higher revenue but materially weaker operating economics. Client concentration remains central to the business profile, even though the company has added services such as CCTV installation and maintenance.
Price performance
The share closed at LKR 296 on 2026-08-07. It gained 61.6% over one year, substantially ahead of the ASPI's 9.5% return, while its three-month decline of 6.5% was slightly less severe than the index's 7.1% fall.
The price sits at 78.8% of its 52-week range, 9.3% below the high. Recent 60-day volatility was 38.9%, below its own one-year volatility of 50.1%, while 20-day average volume was 34.4% above the 60-day average. These are observed trading patterns, and the data does not establish why the share outperformed over one year.
Valuation
CDC trades on a P/E of 8.88, with the multiple at the 29th percentile of its sector. Its P/B of 0.787 is also near the cheaper end of the group, at the 25th percentile, while annual ROE was 9.5%, so the discount is not being supported by unusually high returns on equity.
The dividend yield is 2.4% and sits at the 42nd sector percentile. The payout has been steady at LKR 7.0 per share from FY2023 through FY2025, rather than showing a recent cut or increase, which makes the yield a stable but not especially high cash-return feature.
News and sentiment
Direct coverage is thin: there were zero material company articles in the latest 90-day window, with no positive, negative or neutral articles recorded.
The latest confirmed corporate action was the FY2025 final dividend, which went ex-dividend on 2026-03-31 and was payable on 2026-04-23. No undated corporate actions are recorded.
Financials
In the quarter ended 2026-06-30, revenue rose to LKR 227.6 million, up 23.2% year-on-year, but net profit fell to LKR 47.7 million, down 19.9%. Operating profit also fell 18.8%, showing that the revenue increase did not translate into operating earnings.
Gross margin contracted to 29.6% from 40.6%, operating margin to 21.6% from 32.8%, and net margin to 20.9% from 32.2%. Each margin ranked sixth of seven comparable June quarters in the company's history, placing the latest print among its weakest like-for-like results. The below-line drag was LKR 1.6 million, so the profit decline was primarily operating rather than caused by finance costs, tax or other below-line items.
The latest figures are on the same company basis as the year-ago quarter. The annual record also shows pressure: FY2025 net profit fell 27.6% year-on-year, despite revenue growth of 15.2%.
Risks
The most important financial risk is weak cash conversion. Operating cash flow converted only 0.37x of operating profit in FY2025, meaning reported profit did not arrive fully as cash, while free cash flow was LKR 98.0 million after capital expenditure.
The balance sheet otherwise provides protection: interest cover was 43.0x and the current ratio was 11.21x in FY2025. Gearing was not disclosed in the annual balance-sheet data, and total debt was also not reported for that period, so leverage cannot be assessed precisely from the available figures.
CDC's sole-client structure is an additional concentration risk. Sector conditions are mixed: construction activity was supported by a June PMI reading of 60, but reported skilled-labour and bitumen shortages could raise execution costs across the property-construction sector. The latest market backdrop also included fuel-price volatility and inflation above the central bank's upper band.
Outlook
The next company-specific event is the filing for the quarter ending 2026-09-30. As at 2026-08-08, the exchange-based filing window runs from 2026-10-28 to 2027-01-26, with the latest quarter's weak like-for-like margins making that filing the clearest test of whether the revenue-profit gap persists.
Lower market interest rates could reduce financing pressure across the economy, but CDC's latest quarter does not disclose finance costs and its recent annual interest cover was already high. The available data therefore cannot establish that rate movements will materially improve CDC's earnings; the next filing will provide the more relevant evidence.